Squarepoint
AXSM icon

Squarepoint’s Axsome Therapeutics AXSM Stock Holding History

Squarepoint’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$237K Buy
1,400
+100
+8% +$17.3K ﹤0.01% 3865
2025
Q4 		$237K Buy
+1,300
New +$181K ﹤0.01% 3769
2025
Q2 		– Sell
-9,200
Closed -$1.07M – 4481
2025
Q1 		$1.07M Sell
9,200
-4,200
-31% -$478K ﹤0.01% 2596
2024
Q4 		$1.13M Buy
13,400
+2,900
+28% +$267K ﹤0.01% 2944
2024
Q3 		$944K Buy
+10,500
New +$917K ﹤0.01% 2650

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's AXSM Position: Q1 2026 in Review

Squarepoint reduced its Axsome Therapeutics (AXSM) stake by 26% in Q1 2026, selling an estimated $7.06M and leaving 114,102 shares worth $19.3M. The position accounts for 0.02% of the portfolio, ranked #728.

Squarepoint first reported a position in AXSM in Q3 2017 and has held it in 19 quarters since. The position peaked at $28.3M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Squarepoint held 114,102 shares of Axsome Therapeutics worth $19.3M as of Q1 2026.
  • Squarepoint sold 40,898 Axsome Therapeutics shares in Q1 2026, an estimated $7.06M.
  • Axsome Therapeutics made up 0.02% of Squarepoint's portfolio in Q1 2026, its #728 holding.
  • Squarepoint first reported a position in Axsome Therapeutics in Q3 2017 and has held it in 19 quarters since.
  • Squarepoint's Axsome Therapeutics position peaked at $28.3M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.